Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study

Mounir Ait-Khaled; James Oyee; Adrian Yit Reen Ooi; Brian Wynne; Andres Maldonado; Bryn Jones; Tao Wang

doi:10.1093/ofid/ofae227

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study

Open Forum Infect Dis. 2024 May 2;11(5):ofae227. doi: 10.1093/ofid/ofae227. eCollection 2024 May.

Authors

Mounir Ait-Khaled¹, James Oyee², Adrian Yit Reen Ooi³, Brian Wynne⁴, Andres Maldonado⁵, Bryn Jones¹, Tao Wang⁶

Affiliations

¹ ViiV Healthcare, Brentford, United Kingdom.
² GSK, Brentford, United Kingdom.
³ ViiV Healthcare, Singapore.
⁴ ViiV Healthcare, Durham, North Carolina, USA.
⁵ ViiV Healthcare, Wavre, Belgium.
⁶ GSK, Shanghai, China.

Abstract

TANGO results have established the durable efficacy of dolutegravir/lamivudine in virologically suppressed individuals who switched from 3- or 4-drug tenofovir alafenamide (TAF)-based regimens. In this post hoc subgroup analysis, 144-week efficacy and tolerability of dolutegravir/lamivudine in participants who switched from elvitegravir/cobicistat/emtricitabine/TAF were consistent with the overall switch population.

Clinical trials registration: NCT03446573.

Keywords: HIV-1; dolutegravir/lamivudine; elvitegravir; switch study; virologically suppressed.

Publication types

Clinical Trial

Associated data

ClinicalTrials.gov/NCT03446573